[EN] TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS<br/>[FR] DÉRIVÉS DE TRIAZOLE ET LEUR UTILISATION POUR DES TROUBLES NEUROLOGIQUES
申请人:HOFFMANN LA ROCHE
公开号:WO2012062687A1
公开(公告)日:2012-05-18
The present invention is concerned with novel triazole compounds of formula (I) wherein A, X, Y, Z, R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of present invention have affinity and selectivity for the GABA A α5 receptor. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.
本发明涉及一种新型三唑化合物,其化学式为(I),其中A、X、Y、Z、R1、R2和R3如本文所述,以及其药学上可接受的盐和酯。本发明的活性化合物具有对GABA A α5受体的亲和力和选择性。此外,本发明涉及制备化合物(I)的方法,包括它们的药物组合物以及它们作为药物的用途。
Triazole compounds I
申请人:Hernandez Maria-Clemencia
公开号:US08742097B2
公开(公告)日:2014-06-03
The present invention is concerned with novel triazole compounds of formula (I)
wherein A, X, Y, Z, R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of present invention have affinity and selectivity for the GABA A α5 receptor. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.
本发明涉及一种新型的三唑类化合物,其化学式为(I),其中A,X,Y,Z,R1,R2和R3如本文所述,以及其药学上可接受的盐和酯。本发明的活性化合物具有对GABA A α5受体的亲和力和选择性。此外,本发明涉及化合物(I)的制造,包括它们的药物组合物和它们作为药物的用途。
TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS
申请人:F.Hoffmann-La Roche AG
公开号:EP2638029A1
公开(公告)日:2013-09-18
US8742097B2
申请人:——
公开号:US8742097B2
公开(公告)日:2014-06-03
NOVEL TRIAZOLE COMPOUNDS I
申请人:Hernandez Maria-Clemencia
公开号:US20120115844A1
公开(公告)日:2012-05-10
The present invention is concerned with novel triazole compounds of formula (I)
wherein A, X, Y, Z, R
1
, R
2
, and R
3
are as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of present invention have affinity and selectivity for the GABA A α5 receptor. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.
本发明涉及具有以下式(I)的新型三唑化合物,
其中A、X、Y、Z、R1、R2和R3如本文所述,以及其药学上可接受的盐和酯。本发明的活性化合物具有对GABA A α5受体的亲和力和选择性。此外,本发明涉及制备具有式(I)的化合物,包括它们的药物组合物以及它们作为药物的用途。